Skip to main content
David Neskey, MD, Otolaryngology (ENT), Charleston, SC, HCA South Atlantic - Trident Medical Center

DavidMichaelNeskeyMDMSCR, FACS

Otolaryngology (ENT) • Charleston, SC

Head & Neck Oncologic Surgery, Head & Neck Plastic Surgery

Director Head and Neck Translational Research Program Sarah Cannon Research Institute Trident Health HCA Healthcare

Request Appointment

Overview of Dr. Neskey

I received my medical degree from Albany Medical College with a distinction in research in 2006 followed by a residency in Otolaryngology Head and Neck Surgery at the University of Miami. I then completed a fellowship in head and neck surgical oncology at MD Anderson Cancer Center in Houston. This training experience was comprised of two years dedicated to translational science research followed by a year committed to head and neck surgical oncology. I was on faculty at the Medical University of South Carolina in the Department of Otolaryngology–Head and Neck Surgery until 2021. I currently serve as the Director of Head and Neck Translational Research at Sarah Cannon Research Institute.

My clinical focus is on the care of patients with benign and malignant neoplasias of the head and neck including oral cavity, oropharyngeal, laryngeal lesions, and skullbase, advanced melanoma and nonmelanoma skin cancers, and lesions of the salivary glands, thyroid and parathyroids. His specific interests are squamous cell carcinoma of the oral cavity and oropharynx along with advanced skin cancer and skull base tumors.

4.    I have published over 50 peer reviewed articles and book chapters focused on the
molecular pathways and genomic alterations associated with head and neck squamous cell carcinoma. In addition, I have been the principal investigator for several ongoing trials, including a Phase II investigator-initiated trial of nivolumab as a presurgical treatment for patients with oral cavity cancer. I have been continuously funded through the NIH/NIDCR since 2016. I am board certified by the American Board of Otolaryngology and am a member of the American Head and Neck Society, American Academy of Clinical Research, and a Fellow of the American College of Surgeons.

I am currently seeing patients at the Head and Neck Specialists clinic at Trident Medical Center

Education & Training

  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonFellowship, Otolaryngology - Head and Neck Surgery, 2011 - 2014
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Otolaryngology - Head and Neck Surgery, 2006 - 2011
  • Albany Medical College
    Albany Medical CollegeClass of 2006
  • Colby College
    Colby CollegeB.A., Biology, 1995 - 1999

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2014 - 2025
  • GA State Medical License
    GA State Medical License 2022 - 2023
  • TX State Medical License
    TX State Medical License 2013 - 2015
  • American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

  • Best Basic Science Poster 8th International Conference on Head & Neck Cancer, 2012
  • Resident Research Award 2009-2010
  • Distinction in Research 2005-2006
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Evaluating Adjuvant Therapy with Chemoradiation vs Radiation Alone for Patients with HPV-Negative N2a Head and Neck Cancer  
    David M Neskey, Patrik Pipkorn, Joseph Zenga, Evan M Graboyes, JAMA Otolaryngology–Head & Neck Surgery
  • Association of Treatment Delays with Survival for Patients with Head and Neck Cancer  
    Brian Nussenbaum, David M Neskey, Evan M Graboyes, Shaun Nguyen, Graham W Warren, JAMA
  • Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma  
    Neskey DM, Klein JD, Hicks S, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME, JAMA Otolaryngol Head Neck Surg, 9/26/2013
  • Join now to see all

Books/Book Chapters

  • Plastic reconstructive and aesthetic surgery. 
    Chapter: Head and Neck Malignancy. 
    Neskey DM and Weed DWorld Scientific Publishing Ltd., Hackensack, NJ2011

Abstracts/Posters

  • Surgical Salvage for Recurrent Oral Cavity Squamous Cell Carcinoma.
    Neskey DM, Boerner RM, Ward AW, Roberts DB, Kuoni SM, Stoneking JN, Tyler MA, Alukual P, Hutcheson KA, Weber RS, Sturgis EM, Myers JN, Zafereo ME, 5th World Congress - IFNOS and AHNS, New York, NY, 7/26/2014
  • Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma.
    Neskey DM, Klein JD, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME, American Head and Neck Society, Orlando, FL, 4/10/2013
  • MK-1775, A selective Wee1 kinase Inhibitor, Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Squamous Cell Carcinoma of the Head and Neck.
    Osman AA, Monroe M, Alves Ortega M, Neskey DM, Patel AA, Chuang HC, Mason L, Meyn RE Byers L, Katsonis P, Lichtarge O, Myers JN, American Academy of Cancer Research, Washington, DC, 4/6/2013
  • Join now to see all

Authored Content

  • Evaluating Adjuvant Therapy with Chemoradiation vs Radiation Alone for Patients with HPV-Negative N2a Head and Neck CancerAugust 2020

Press Mentions

  • Jessica Thaxton, PhD with MUSC’s Hollings Cancer Center Secures $3.4m to Look at Immunotherapy and Cell Stress
    Jessica Thaxton, PhD with MUSC’s Hollings Cancer Center Secures $3.4m to Look at Immunotherapy and Cell StressJuly 25th, 2020
  • New Associate Directors at Hollings Cancer Center to Advance Cancer Immunology
    New Associate Directors at Hollings Cancer Center to Advance Cancer ImmunologyApril 25th, 2020
  • Studies Show How to Boost Immunotherapy Effectiveness for Patients with Oral-Cavity Squamous Cell Carcinoma
    Studies Show How to Boost Immunotherapy Effectiveness for Patients with Oral-Cavity Squamous Cell CarcinomaNovember 5th, 2021

Grant Support

  • Defining the role of CD26 in checkpoint blockaded induced tumor immunityNational Institute of Dental and Craniofacial Research2020–2022
  • Paul Calebresi Clinical and Translational Oncology Training ProgramNational Cancer Institute2020–2021
  • The tumor suppressor capability of p53 is dependent on Non-muscle Myosin IIA function in Head and Neck Cancer.NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH2016–2019
  • Paul Calebresi Clinical and Translational Oncology Training ProgramNational Cancer Institute2014–2016

Committees

  • Member, Advanced Training Council American Head and Neck Society 2020 - 2021

Research History

  • Cancer Immunology Interim Program Director Hollings Cancer Center2019 - 2020

Professional Memberships

Hospital Affiliations

Dr. David Neskey, Dr. David Neskey, MD, Dr. D Neskey, Dr. David Michael Neskey